Assessment of Vitamin D Supplementation and Immune Function

NCT ID: NCT01399151

Last Updated: 2014-04-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypothesis:

Volunteers with vitamin D insufficiency (serum 25(OH)D 25-50 nmol/L) given intermediate or high dose vitamin D supplements (2,000 or 5,000 IU per day) will have increased production of anti-bacterial peptides and interleukin-1, decreased production of other pro-inflammatory cytokines, increased production of regulatory cytokines and an enhanced T- and B-cell response to a tetanus vaccine compared to vitamin D insufficient subjects given low dose vitamin D supplements (400 IU per day).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Specific Aim 1:

Determine if high dose vitamin D supplements decrease the production of proinflammatory and increase the production of regulatory cytokines and chemokines by innate immune cells stimulated ex vivo.

Specific Aim 2:

Determine if high dose vitamin D supplements decrease serum markers of inflammation and increase serum and cellular levels of defensive molecules (e.g., cathelicidin).

Specific Aim 3:

Determine if high dose vitamin D supplements decrease blood levels of proinflammatory T-helper type 1 (Th1) and Th17 cells and increase levels of anti-inflammatory T-regulatory (Treg) and Th2 cells.

Specific Aim 4:

Determine if high dose vitamin D supplements increase antigen specific T cell and B cell responses after tetanus vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitamin D Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D - Treatment 1

400 IU/day Vitamin D

Group Type EXPERIMENTAL

Vitamin D - Treatment 1

Intervention Type DIETARY_SUPPLEMENT

Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.

Vitamin D- Treatment 2

2,000 IU/day Vitamin D

Group Type EXPERIMENTAL

Vitamin D - Treatment 2

Intervention Type DIETARY_SUPPLEMENT

Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.

Vitamin D- Treatment 3

5,000 IU/day Vitamin D

Group Type EXPERIMENTAL

Vitamin D - Treatment 3

Intervention Type DIETARY_SUPPLEMENT

Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin D - Treatment 1

Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.

Intervention Type DIETARY_SUPPLEMENT

Vitamin D - Treatment 2

Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.

Intervention Type DIETARY_SUPPLEMENT

Vitamin D - Treatment 3

Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 20-49 (men) and 20-45 (women)
* BMI 18.5-30
* Serum 25OH Vitamin D 25-50 nmol/L

Exclusion Criteria

* Pregnant or nursing women
* Daily smoker
* Anemia (Hgb\<12 mg/dL for women and \<13 mg/dL for men) determined at initial visit
* Any report or diagnosis of disease or chronic condition that may affect vitamin D absorption such as cystic fibrosis, celiac disease, surgical removal of part of the stomach or intestines, and some forms of liver disease
* Diagnosis of hyper parathyroidism and chronic granulomatous disease, which increases risk of hypercalcemia.
* Planned to travel to a location at which either altitude or latitude would result in significant vitamin D synthesis during the study period.
* Not previously vaccinated with TT, or vaccinated within five years
* Use of steroids or antibiotics within the past 4 weeks
* Current use of nutritional supplements that may alter immune function such as omega 3 fatty acid supplements
* Current use of anti-inflammatory or anti-convulsion medications
* Self reported history of significant adverse response to previous vaccinations
Minimum Eligible Age

20 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

USDA, Western Human Nutrition Research Center

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Charles Stephensen, PhD

Role: PRINCIPAL_INVESTIGATOR

WHNRC, ARS, University of California Davis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Western Human Nutrition Center, University of California Davis

Davis, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ars.usda.gov/Main/docs.htm?docid=11240

USDA Western Human Nutrition Research Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

USDA CRIS 5306-51530-018-00D

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

WHNRC 213949-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

High-dose Vitamin D Supplements in Older Adults
NCT03613116 ACTIVE_NOT_RECRUITING PHASE2